Short Interest in Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) Increases By 355.3%

Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) was the target of a significant increase in short interest during the month of April. As of April 15th, there was short interest totaling 22,704 shares, an increase of 355.3% from the March 31st total of 4,987 shares. Currently, 1.3% of the shares of the company are sold short. Based on an average daily trading volume, of 21,902 shares, the short-interest ratio is currently 1.0 days.

Bolt Biotherapeutics Trading Up 1.3%

Shares of NASDAQ:BOLT opened at $4.83 on Friday. Bolt Biotherapeutics has a 52-week low of $3.91 and a 52-week high of $9.25. The stock has a market cap of $9.27 million, a price-to-earnings ratio of -0.27 and a beta of 0.86. The company has a quick ratio of 3.59, a current ratio of 3.59 and a debt-to-equity ratio of 0.76. The business has a 50-day moving average price of $4.61 and a 200-day moving average price of $5.23.

Bolt Biotherapeutics (NASDAQ:BOLT) last issued its earnings results on Thursday, March 12th. The company reported ($3.84) earnings per share (EPS) for the quarter, topping the consensus estimate of ($4.27) by $0.43. Bolt Biotherapeutics had a negative net margin of 433.74% and a negative return on equity of 92.54%. The firm had revenue of $2.50 million during the quarter, compared to analysts’ expectations of $0.67 million. Equities analysts predict that Bolt Biotherapeutics will post -11.26 EPS for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in BOLT. Squarepoint Ops LLC raised its holdings in shares of Bolt Biotherapeutics by 19.8% during the third quarter. Squarepoint Ops LLC now owns 14,836 shares of the company’s stock worth $79,000 after purchasing an additional 2,448 shares during the last quarter. Shay Capital LLC purchased a new position in shares of Bolt Biotherapeutics during the third quarter worth $85,000. Susquehanna International Group LLP purchased a new position in Bolt Biotherapeutics during the third quarter valued at approximately $89,000. Nano Cap New Millennium Growth Fund L P purchased a new position in Bolt Biotherapeutics during the fourth quarter valued at approximately $112,000. Finally, T3 Companies LLC purchased a new position in Bolt Biotherapeutics during the fourth quarter valued at approximately $208,000. Hedge funds and other institutional investors own 86.70% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms have issued reports on BOLT. HC Wainwright reaffirmed a “buy” rating and issued a $7.00 price target on shares of Bolt Biotherapeutics in a report on Friday, March 13th. Weiss Ratings restated a “sell (e+)” rating on shares of Bolt Biotherapeutics in a research note on Monday. Two analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Bolt Biotherapeutics has a consensus rating of “Hold” and a consensus target price of $34.00.

Bolt Biotherapeutics Company Profile

Bolt Biotherapeutics is a clinical-stage immuno-oncology company focused on developing novel targeted therapies that engage both innate and adaptive immune responses against cancer. The company’s proprietary Biologics-Driven Checkpoint (BDC) platform combines tumor-targeting antibodies with innate immune agonists to activate antigen-presenting cells within the tumor microenvironment, thereby promoting robust T-cell mediated tumor cell killing. Its lead candidate, BDC-1001, couples a HER2-directed monoclonal antibody with a Toll-like receptor 7/8 agonist and is currently in Phase I clinical trials for HER2-positive solid tumors.